Cadila Healthcare announced today that Zydus Cadila has received final approval from the US health regulatory authority, USFDA to market Lansoprazole capsules. These capsules would be used in treating ulcers and other gastric and esophageal conditions related to excessive stomach acid.
Zydus Cadila receives FDA Green Signal for Anti-Ulcer Drug
Cadila Healthcare announced today that Zydus Cadila has received final approval from the US health regulatory authority, USFDA to market Lansoprazole capsules. These capsules would be used in treating ulcers and other gastric and esophageal conditions related to excessive stomach acid.
Zydus Cadila is a Ahmedabad based firm and has its global operations spread across USA, Europe, Japan, Brazil, South Africa and 25 other emerging markets. It is an innovative global pharmaceutical company that is involved in discovering, developing, manufacturing and marketing a broad range of healthcare products. The group’s operations range from API to formulations, animal health products and cosmeceuticals.
United States Food and Drug Administration (USFDA) has permitted Zydus Cadila, to market Lansoprazole delayed release (DR) Capsules in different strengths of 15 mg and 30 mg. As stated by the company, the company group has 81 approvals now and so far has filed 186 abbreviated new drug applications (ANDAs) since the commencement of filing process in FY 2003-2004.